Research output per year
Research output per year
Personal profile
Public Profile
David Yeung is a postdoctoral research fellow with the Precision Medicine Theme at the SHAMRI. He also has positions with the Royal Adelaide Hospital and SA Pathology as a practicing haematologist and haemato-pathologist, and has affiliations with both the University of Adelaide and the University of South Australia. He had training in clinical and laboratory haematology in Sydney before completing his PhD in Adelaide. His focus is on improving outcomes for patients with chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL). Along with Prof Tim Hughes, David leads several national CML clinical trials, with the aim of optimising the use to tyrosine kinase inhibitors leading to improved efficacy and reduced toxicity. Innovative correlative study research projects attached to this clinical trials allow further understand of the biology underlying resistant cases. David also has project with Prof Deb White of the Cancer Theme, who heads the national effort in understanding and improving outcomes in high risk ALL. He has co-authored 24 publications in peer reviewed journals and 2 book chapters in postgraduate text books.
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia
Downes, C. E. J., McClure, B. J., Bruning, J. B., Page, E., Breen, J., Rehn, J., Yeung, D. T. & White, D. L., 10 Aug 2021, In: NPJ precision oncology. 5, 1, p. 75Research output: Contribution to journal › Article › peer-review
-
A Systematic Review of the Clinical Pharmacokinetics, Pharmacodynamics and Toxicodynamics of Ganciclovir/Valganciclovir in Allogeneic Haematopoietic Stem Cell Transplant Patients
Selby, P. R., Shakib, S., Peake, S. L., Warner, M. S., Yeung, D., Hahn, U. & Roberts, J. A., Jun 2021, In: Clinical Pharmacokinetics. 60, 6, p. 727-739 13 p.Research output: Contribution to journal › Review article › peer-review
-
Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia
Shanmuganathan, N., Pagani, I. S., Ross, D. M., Park, S., Yong, A. S. M., Braley, J. A., Altamura, H. K., Hiwase, D. K., Yeung, D. T., Kim, D. W., Branford, S. & Hughes, T. P., 4 Mar 2021, In: Blood. 137, 9, p. 1196-1207 12 p.Research output: Contribution to journal › Article › peer-review
7 Citations (Scopus) -
In-vitro modeling of TKI resistance in the high-risk B-cell acute lymphoblastic leukemia fusion gene RANBP2-ABL1 - implications for targeted therapy
Heatley, S. L., Asari, K., Schutz, C. E., Leclercq, T. M., McClure, B. J., Eadie, L. N., Hughes, T. P., Yeung, D. T. & White, D. L., 2021, In: Leukemia and Lymphoma. 62, 5, p. 1157-1166 10 p.Research output: Contribution to journal › Article › peer-review
-
Polycomb Factor PHF19 Controls Cell Growth and Differentiation Toward Erythroid Pathway in Chronic Myeloid Leukemia Cells
García-Montolio, M., Ballaré, C., Blanco, E., Gutiérrez, A., Aranda, S., Gómez, A., Kok, C. H., Yeung, D. T., Hughes, T. P., Vizán, P. & Di Croce, L., 29 Apr 2021, In: Frontiers in Cell and Developmental Biology. 9, 655201.Research output: Contribution to journal › Article › peer-review
Open Access